<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04389983</url>
  </required_header>
  <id_info>
    <org_study_id>00087958</org_study_id>
    <nct_id>NCT04389983</nct_id>
  </id_info>
  <brief_title>Ketone Levels Achieved After Medium Chain Triglyceride (MCT) Oil</brief_title>
  <official_title>Ketone Levels Achieved After Medium Chain Triglyceride (MCT) Oil</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessing Ketone levels achieved after varying doses of Medium Chain Triglyceride (MCT) oil
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessing Ketone levels achieved after varying doses of Medium Chain Triglyceride (MCT) oil
      in three study populations: &lt;65 year healthy, 65 and older healthy, and Alzheimer's disease.

      Each subject attends for 4 study days, receiving incrementally larger MCT doses at each visit
      for 0g, to 14g, to 28g to 42g.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2, 2019</start_date>
  <completion_date type="Actual">April 15, 2020</completion_date>
  <primary_completion_date type="Actual">May 24, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>3 months</time_frame>
    <description>Calculation of Cmax to varying doses in each subject and in different study arms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum plasma concentration (tmax)</measure>
    <time_frame>3 months</time_frame>
    <description>Calculation of tmax to varying doses in each subject and in different study arms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>3 months</time_frame>
    <description>Calculation of AUC to varying doses in each subject and in different study arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>weight</measure>
    <time_frame>3months</time_frame>
    <description>measured in kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>height</measure>
    <time_frame>3 months</time_frame>
    <description>measured in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>3months</time_frame>
    <description>Calculated BMI (ht/m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat</measure>
    <time_frame>3 months</time_frame>
    <description>% measured by bioimpedence scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>Healthy, under 65 years</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Four study days. Day 1 administered 0g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 2 administered 14g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 3 administered 28g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 4 administered 42g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter (All MCT doses administered as a single dose at time 0)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy, over 65 years</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Four study days. Day 1 administered 0g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 2 administered 14g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 3 administered 28g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 4 administered 42g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter.
(All MCT doses administered as a single dose at time 0)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alzheimer's Disease subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Four study days. Day 1 administered 0g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 2 administered 14g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 3 administered 28g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter Day 4 administered 42g MCT oil with baseline and hourly betahydroxybutyrate (BHB) measures (by fingerstick test) for 5 hours thereafter.
(All MCT doses administered as a single dose at time 0)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Medium Chain Triglyceride oil</intervention_name>
    <description>Bulletproof Braine Octane MCT oil</description>
    <arm_group_label>Alzheimer's Disease subjects</arm_group_label>
    <arm_group_label>Healthy, over 65 years</arm_group_label>
    <arm_group_label>Healthy, under 65 years</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult, healthy or with AD

        Exclusion Criteria:

          -  unable to attend all study days

          -  coconut allergy

          -  Diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Angela Juby</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 7, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2020</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Angela Juby</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>MCT oil</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

